Cortexyme, Inc. (CRTX) News
Filter CRTX News Items
CRTX News Results
|Loading, please wait...|
CRTX News Highlights
- CRTX's 30 day story count now stands at 4.
- Over the past 13 days, the trend for CRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CRTX are DRUG, BIO and GENE.
Latest CRTX News From Around the Web
Below are the latest news stories about Cortexyme Inc that investors may wish to consider to help them evaluate CRTX as an investment opportunity.
Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Ab...
The clinical-stage drugmaker's shares imploded last year in response to the failure of its lead Alzheimer's disease candidate atuzaginstat in a combined phase 2/3 study. Specifically, atuzaginstat reportedly missed both of its co-primary endpoints in the phase 2/3 Gain trial as a treatment for mild to moderate forms of Alzheimer's disease. Since announcing these disappointing trial results late last year, Cortexyme has said that it plans to trial the drug yet again.
In a market made up of stocks, these three most-shorted stocks look poised to deliver a much happier 2022 to bullish investors.
If you want to know who really controls Cortexyme, Inc. ( NASDAQ:CRTX ), then you'll have to look at the makeup of its...
Cortexyme Inc. (NASDAQ:CRTX) traded at $12.81 at close of the session on Tuesday, 12/21/21, made an upward move of 2.81% on its previous days price. Looking at the stock we see that its previous close was $12.46 and the beta (5Y monthly) reads 0.75 with the days price range being $12.19 $13.179. In terms Wall Streets Take On Cortexyme Inc. (NASDAQ: CRTX) Stock. Read More »
Cedar Brook Financial Partners LLC purchased a new stake in shares of Cortexyme, Inc. (NASDAQ:CRTX) in the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 2,218 shares of the biopharmaceutical companys stock, valued at approximately $203,000. Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Ameritas 
Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates!
No summary available.
In the last trading session, 1.34 million shares of the Cortexyme Inc. (NASDAQ:CRTX) were traded. Most recently the companys share price was $11.35, and it changed around -$0.96 or -7.80% from the last close, which brings the market valuation of the company to $353.44M. CRTX currently trades at a discount to its 52-week high of Cortexyme Inc. (NASDAQ: CRTX): The Stock We Should Bet On For Economic Growth In The Months To Come Read More »
Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called "meme stocks" generated jaw-dropping gains for investors earlier this year due to this phenomenon. The mechanics of a short squeeze are fairly straightforward.